Altitude Life Science Ventures
Venture firm that invests in early-stage life science companies and provides IP-focused strategic planning and operational support. Investment scope includes therapeutics, diagnostics, gene editing, AI/ML therapeutics, autonomous science, medical devices, drug delivery platforms and sequencing-related technologies. Emphasizes extended technical and intellectual property due diligence to support commercialization and value preservation.
Industries
Nr. of Employees
small (1-50)
Altitude Life Science Ventures
Durango, Colorado, United States, North America
Products
Tessera Therapeutics
Pioneering Gene Writing—a new genome engineering technology that writes therapeutic messages into the genome to treat diseases at their source.
Altos Labs
Focused on cellular rejuvenation programming to restore cell health and resilience, with the goal of reversing disease to transform medicine.
Aera Therapeutics
Proprietary delivery platform, based on endogenous human proteins, offers the potential to enable genetic medicines across a broad range of modalities and therapeutic areas.
Ring Therapeutics
Developing first-in-class gene therapies, Anellovector therapies, using a novel viral vector platform based on its groundbreaking work on the human commensal virome.
City Therapeutics
RNAi platform derived from cityRNAs.
Interdict Bio
Developing a small molecule therapeutics platform for addressing strongly validated yet historically undruggable targets in oncology, rare diseases, neurodegeneration and autoimmunity.
Tessera Therapeutics
Pioneering Gene Writing—a new genome engineering technology that writes therapeutic messages into the genome to treat diseases at their source.
Altos Labs
Focused on cellular rejuvenation programming to restore cell health and resilience, with the goal of reversing disease to transform medicine.
Aera Therapeutics
Proprietary delivery platform, based on endogenous human proteins, offers the potential to enable genetic medicines across a broad range of modalities and therapeutic areas.
Ring Therapeutics
Developing first-in-class gene therapies, Anellovector therapies, using a novel viral vector platform based on its groundbreaking work on the human commensal virome.
City Therapeutics
RNAi platform derived from cityRNAs.
Interdict Bio
Developing a small molecule therapeutics platform for addressing strongly validated yet historically undruggable targets in oncology, rare diseases, neurodegeneration and autoimmunity.
Services
Equity investments in early-stage companies across therapeutics, diagnostics, platform technologies and related commercial applications of advances in biology and chemistry.
Advisory services to design and execute multi-layered patent portfolios that track technology maturation and support commercialization and licensing.
Extended diligence including scientific, manufacturing and regulatory assessments to inform investment decisions and commercialization planning.
Equity investments in early-stage companies across therapeutics, diagnostics, platform technologies and related commercial applications of advances in biology and chemistry.
Advisory services to design and execute multi-layered patent portfolios that track technology maturation and support commercialization and licensing.
Extended diligence including scientific, manufacturing and regulatory assessments to inform investment decisions and commercialization planning.
Expertise Areas
- Venture investment for early-stage life sciences
- Intellectual property strategy and patent portfolio planning
- Technical and IP-focused due diligence
- Commercialization and regulatory planning support
Key Technologies
- Gene editing
- AI / machine learning for drug discovery
- Autonomous laboratory automation
- RNA therapeutics (e.g., RNA expression platforms, RNAi)
News & Updates
Report of six-month clinical results from a study of islet cell transplantation without immunosuppression (portfolio company news featured on firm site).
FDA approval announcement for a portfolio company treatment described on firm site.
Announcement of a research collaboration leveraging RNAi technologies (featured on firm site news).
FDA approval news for a portfolio company device highlighted on the firm site.
Report of six-month clinical results from a study of islet cell transplantation without immunosuppression (portfolio company news featured on firm site).
FDA approval announcement for a portfolio company treatment described on firm site.
Announcement of a research collaboration leveraging RNAi technologies (featured on firm site news).
FDA approval news for a portfolio company device highlighted on the firm site.